COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluate Efficacy, Safety and PK of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00071201
Recruitment Status : Completed
First Posted : October 17, 2003
Last Update Posted : October 16, 2013
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:
This is a multi-center phase 3, open-label, parallel-group study designed to evaluate the efficacy, safety and pharmacokinetics of adefovir dipivoxil liquid suspension in patients with chronic hepatitis B and varying degrees of renal impairment.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis B Drug: Adefovir Dipivoxil for oral suspension, 2 mg/mL Phase 3

Detailed Description:

Approximately 48 patients with chronic hepatitis B will be enrolled into four groups representing varying degrees of renal function. Grouping will be achieved through estimation of creatinine clearance (CLcr) using the Cockcroft-Gault method of calculation at the time of screening:

Group 1: Mild (Clcr = greater than or equal to 50 to less than 80 mL/min)

Group 2: Moderate (Clcr = greater than or equal to 20 to less than 50 mL/min)

Group 3: Severe (Clcr = greater than or equal to 10 to less than 20 mL/min)

Group 4A-B: End stage renal disease (ESRD) including hemodialysis:

  • Group 4A (Clcr = less than 10 mL/min)
  • Group 4B (Patients undergoing hemodialysis)

At the baseline visit (day 0), blood and urine samples will be collected pre-dose (prior to 0 hour) after which patients will receive an oral dose of liquid adefovir dipivoxil according to the treatment guideline outlined in the protocol.

Pharmacokinetic parameters in plasma will be determined for the day 0 and week 12 visits for all patients and at the week 48 visit for group 1, 2, 3, and 4A patients. Pharmacokinetic parameters in urine will be determined for the day 0, week 12 and week 48 visits for group 1, 2, 3, and 4A patients.

At week 4, 8, 16, 20, 24, 28, 32, 36, 40, and 44 visits, pharmacokinetic assessments in plasma will be determined pre-dose (Ctrough levels) in groups 1, 2, 3, and 4A. For group 4B patients, pharmacokinetic assessments will be determined at weeks 4 and 8 prior to and upon completion of hemodialysis.

Evaluations of safety and efficacy will be conducted at 4 weekly intervals up to week 48 for groups 1, 2, 3, and 4A, and up to week 12 for group 4B. At these visits, patients will receive the next study medication allocation. Study medication administration will continue for up to a total of 48 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 48 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Varying Degrees of Renal Impairment
Study Start Date : June 2003
Actual Primary Completion Date : March 2006
Actual Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Male or female ages 18 through 65 years
  • Able to give written informed consent and comply with the requirements of the study
  • Females of childbearing potential must have a negative serum pregnancy test at screening and must use effective methods of contraception throughout the study.
  • Positive serum HBV DNA equal to or greater than 100,000 copies/mL
  • Patients with abnormal renal function, defined as a calculated creatinine clearance less than 80 mL/min, or end stage renal disease undergoing hemodialysis
  • For non-hemodialysis patients, renal function must be "stable"
  • ALT value equal to or greater than 1.2 to equal to or less than 15 times the upper limit of normal on at least two occasions, or histological evidence of necroinflammation and/or fibrosis
  • Compensated liver disease with the following:

    • Prothrombin time equal to or less than to 1 second above normal range
    • Total bilirubin equal to or less than to 2.5 mg/dL or normal direct bilirubin
  • No history of variceal bleeding or encephalopathy
  • HIV, HCV, and HDV seronegative
  • Adequate hematological function defined as:

    • Absolute neutrophil count equal to or greater than 750/mm3
    • Platelets equal to or greater than 50,000/mm3
    • Hemoglobin equal to or greater than 7.5 g/dL


  • Inability to comply with study requirements
  • Lactating or pregnant females
  • History or current manifestations of clinically significant cardiac, respiratory, endocrine (including diabetes mellitus), metabolic, gastrointestinal, dermatological, infectious, malignant, hematological, neurological, rheumatologic or psychiatric disorder, which is not related to the patient's renal insufficiency or deemed by the investigator to preclude suitability for pharmacokinetic assessment or interfere with patient treatment, assessment, or compliance with the protocol
  • Received interferon within 6 months prior to study screening
  • Bone marrow transplant recipients
  • Renal transplant less than 6 months prior to study entry, or clinical evidence of rejection
  • Patients expected to receive organ transplantation within 48 weeks
  • Evidence of active liver disease due to other causes
  • Patients taking chemotherapeutic agents within 2 months or expected to receive these agents during the study
  • Previous participation in an investigational trial involving any investigational compound within 2 months, or within 5 half-lives of the study drug if sooner
  • History of alcohol or drug abuse sufficient to hinder compliance with protocol
  • Child-Pugh-Turcotte score over 9
  • Evidence of hepatic mass suggestive of hepatocellular carcinoma
  • History of malignancy other than basal cell carcinoma or treated cervical carcinoma in situ or cervical dysplasia
  • The use of systemic drugs with potential activity against HBV for a period of more than 12 weeks in duration at any time
  • The use of adefovir dipivoxil for a period of more than 12 weeks in duration at any time. Hemodialysis patients may be enrolled regardless of prior treatment duration with adefovir dipivoxil if treatment completed greater than or equal to 16 weeks before study.
  • Hypersensitivity to nucleoside and/or nucleotide analogs
  • Received hepatotoxic drugs within 2 months or plan to receive them
  • Received nephrotoxic drugs or competitors of renal excretion within 2 months or plan to receive them, except for transplant patients
  • Current use of other pivalic acid containing medications
  • Patients undergoing continuous ambulatory peritoneal dialysis (CAPD)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00071201

Layout table for location information
United States, California
Gilead Sciences, Inc. 333 Lakeside Drive
Foster City, California, United States, 94404
Sponsors and Collaborators
Gilead Sciences
Additional Information:
Layout table for additonal information
Responsible Party: Gilead Sciences Identifier: NCT00071201    
Other Study ID Numbers: GS-02-526
First Posted: October 17, 2003    Key Record Dates
Last Update Posted: October 16, 2013
Last Verified: October 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Adefovir dipivoxil
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents